MA42913A - Pyridazinones et leur utilisation dans le traitement du cancer - Google Patents

Pyridazinones et leur utilisation dans le traitement du cancer

Info

Publication number
MA42913A
MA42913A MA042913A MA42913A MA42913A MA 42913 A MA42913 A MA 42913A MA 042913 A MA042913 A MA 042913A MA 42913 A MA42913 A MA 42913A MA 42913 A MA42913 A MA 42913A
Authority
MA
Morocco
Prior art keywords
pyridazinones
cancer
treatment
Prior art date
Application number
MA042913A
Other languages
English (en)
Inventor
Elias Set Jenö Arnér
Nathan Patrick Coussens
Thomas S Dexheimer
Ajit Jadhav
Diane Karen Luci
David Joseph Maloney
Anton Simeonov
William Chester Stafford
Original Assignee
Arner Elias Set Jenoe
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arner Elias Set Jenoe, Us Health filed Critical Arner Elias Set Jenoe
Publication of MA42913A publication Critical patent/MA42913A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA042913A 2015-08-07 2016-08-05 Pyridazinones et leur utilisation dans le traitement du cancer MA42913A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1514015.5A GB201514015D0 (en) 2015-08-07 2015-08-07 Novel pyridazinones and their use in the treatment of cancer

Publications (1)

Publication Number Publication Date
MA42913A true MA42913A (fr) 2018-08-01

Family

ID=54200420

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042913A MA42913A (fr) 2015-08-07 2016-08-05 Pyridazinones et leur utilisation dans le traitement du cancer

Country Status (5)

Country Link
US (1) US11110089B2 (fr)
EP (1) EP3331878A1 (fr)
GB (1) GB201514015D0 (fr)
MA (1) MA42913A (fr)
WO (1) WO2017027357A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202007535VA (en) * 2018-02-12 2020-09-29 Cinda Pharma Ab Thioredoxin reductase inhibitors for use in the treatment of cancer
CN112996795B (zh) 2018-09-18 2024-11-12 尼坎治疗公司 作为src同源-2磷酸酶抑制剂的稠合的三环衍生物
EP4076448A4 (fr) 2019-12-20 2024-03-27 Tenaya Therapeutics, Inc. Oxadiazoles fluoroalkylés et leurs utilisations
EP4333841A1 (fr) 2021-05-04 2024-03-13 Tenaya Therapeutics, Inc. 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, inhibiteurs de hdac6 pour utilisation dans le traitement des maladies métaboliques et de l'icfep

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
JP5423679B2 (ja) * 2007-10-31 2014-02-19 日産化学工業株式会社 ピリダジノン化合物及びｐ２ｘ７受容体阻害剤
DE102007061963A1 (de) * 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
AU2012382373A1 (en) 2012-06-12 2014-12-11 Abbvie Inc. Pyridinone and pyridazinone derivatives
CN103864769B (zh) * 2012-12-14 2016-11-02 上海工程技术大学 一种噁二唑化合物及其制备方法
KR20170092634A (ko) 2014-12-05 2017-08-11 에이엔2에이치 디스커버리 리미티드 파킨 리가제 활성화 방법 및 조성물

Also Published As

Publication number Publication date
GB201514015D0 (en) 2015-09-23
EP3331878A1 (fr) 2018-06-13
WO2017027357A8 (fr) 2017-04-20
US11110089B2 (en) 2021-09-07
US20200113897A1 (en) 2020-04-16
WO2017027357A1 (fr) 2017-02-16

Similar Documents

Publication Publication Date Title
MA45122A (fr) Inhibiteurs hétérocycliques de cbp/ep300 et leur utilisation dans le traitement du cancer
FR22C1011I2 (fr) Promedicaments de fumarates et leur utilisation pour le traitement de diverses maladies
MA43163A (fr) Polypeptides à domaine extracellulaire cd80 et leur utilisation dans le traitement du cancer
IL283086A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
MA39960A (fr) Composés imidazo[4,5c]quinoline-2-one et leur utilisation dans le traitement du cancer
MA52886A (fr) Composés de purinone et leur utilisation dans le traitement du cancer
PL3303632T3 (pl) Terapeutyczne i diagnostyczne sposoby stosowane w nowotworze
HUE054548T2 (hu) Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében
IL257105A (en) Modified cells and methods of therapy
IL258955A (en) Compositions and methods for treatment of cancer
MA41316A (fr) Gènes de détermination du sexe et leur utilisation en reproduction
LT3240554T (lt) Blautia stercosis ir wexlerae, skirtos naudoti uždegiminių ir autoimuninių ligų gydymui
EP2831278A4 (fr) Aptamères dirigés contre pdgf et vegf et leur utilisation dans le traitement d'états à médiation par pdgf et vegf
MA42420A (fr) Vaccins pour le traitement et la prévention du cancer
MA42915A (fr) Pyridines et leur utilisation dans le traitement du cancer
EP3937980A4 (fr) Miarn modifiés et leur utilisation dans le traitement du cancer
MA47450A (fr) Sulfinylpyridines et leur utilisation dans le traitement du cancer
MA47452A (fr) Pyridines à substitution hétérocyclylsulfonyle et leur utilisation dans le traitement du cancer
DK3439663T3 (da) Fremgangsmåder til behandling af pædiatriske cancere
MA47458A (fr) Pyridines à substitution hydrocarbylsulfonyle et leur utilisation dans le traitement du cancer
MA47451A (fr) Pyridines à substitution hétéroarylsulfonyle et leur utilisation dans le traitement du cancer
EP3331984A4 (fr) Systèmes et procédés de traitement d'allogreffe rapides
EP2969002A4 (fr) Utilisation de levocetirizine et montelukast dans le traitement de blessure traumatique
DK3253208T3 (da) Kombinationsterapier til anvendelse i behandlingen af brystcancer
EP3258964A4 (fr) Détection et traitement de tumeurs malignes dans le snc